Versantis AG
Conquer liver diseases and saves lives
Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse the multi-organ complications arising from liver cirrhosis. It was shown to be safe and well tolerated in a Ph1b study with positive efficacy outcomes, and is now ready to start Phase 2a clinical investigations. VS-01 was granted orphan drug designations by the FDA and EMA, which help streamlining its clinical development pathway.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
19.09.2022
GENFIT acquires Swiss biotech Versantis for up to CHF105 million (startupticker.ch)
28.12.2021
Change of leadership at Swiss deeptech startups (startupticker.ch)
08.09.2021
U.S. FDA grants Versantis Orphan Drug Designation (startupticker.ch)
Last Tweets
No Jobs
Videos
Trailer of the company
The product by the founders
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Technology
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
>>Venture>>
The venture business plan competition takes place every year and combines a competition, learning events and contact form in one. It is an initiative of the ETH Zurich, CTI and McKinsey.
TOP 100 Scale-ups
Being among the TOP 100 Startups in Switzerland has become a seal of approval for founders, and the TOP 100 Swiss Startup Ranking provides them with the recognition they deserve. As startups cannot appear in the startup ranking for more than five years after incorporation, the TOP 100 Swiss Scale-up Ranking has been introduced. A growth jury is asked to select the TOP 100 Swiss Scale-ups. These companies, aged five up to 10 years, show the greatest potential for further growth and represent the future Swiss unicorns
Versantis AG
Conquer liver diseases and saves lives
Website:
www.versantis.ch
Genfit
Headquarter:
Zürich
Foundation Date:
March 2015
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
Support received
